October 25, 2021
Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...
Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. In...
3 University Plaza Drive, Ste 116Hackensack, NJ 07601
© 2021 CMSC